Priority Review Granted for PolarityBio’s SkinTE for Treatment of Diabetic Foot Ulcers
September 24, 2026
PolarityBio, a biotechnology company based in Salt Lake City, Utah, announced today that the FDA has accepted its Biologics License Application (BLA) and granted Priority Review for SkinTE, an autologous multicellular therapy designed to treat Wagner Grade 1 diabetic foot ulcers (DFUs). Ahead of its target PDUFA date of March 16, 2027, PolarityBio continues to advance its market access and commercial readiness strategy. DFUs affect ~18.6 million people worldwide each year, including ~1.6 million people annually in the US. Given the risk of hospitalization and infection associated with chronic, non-healing wounds and limited treatment options, SkinTE could expand treatment offerings for a difficult-to-treat condition that affects a substantial population.
Recent News
- Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA Initiation in Adults with IBS-C
- Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
- Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
- Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
- BlueWind Medical Announces Humana Coverage of Revi® for Urgency Urinary Incontinence, Expanding Access to Millions of Patients
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
